News

The 50 best-funded biotech companies of 2026

2026-08-14

This ranking tracks 50 private biotechs that announced or disclosed financing between January 1 and August 12, 2026, based on cumulative equity raised. Isomorphic Labs, despite raising $2.7 billion, is excluded due to Alphabet's majority control, leaving Rakuten Medical at the top with over $809 million. Earendil Labs ($787M) and NewLimit ($760M) round out the top three, focusing on AI-driven biologics and longevity medicine, respectively.

MORE DETAILS

In Vitro Diagnostic Industry in China - Urine

2026-08-03

MORE DETAILS

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

2026-08-03

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026.

MORE DETAILS

"BMS Unleashes Life Sciences' Most Powerful AI Supercomputer with NVIDIA's Next-Gen Rubin GPUs"

2026-07-29

Bristol Myers Squibb is deploying an NVIDIA DGX SuperPOD with eight Vera Rubin NVL72 racks (576 Rubin GPUs), claiming it as life sciences' most powerful single-owned AI infrastructure. This follows Lilly's October 2025 supercomputer and Roche's March 2026 AI factory. BMS, which has operated a DGX SuperPOD since 2024, is expanding and combining systems. The new cluster offers ~10.1 exaflops peak dense FP8 training performance and 166 TB memory.

MORE DETAILS

FDA approves Freenome's blood test for colorectal cancer screening

2026-07-28

The U.S. FDA has approved Freenome's SimpleScreen CRC, a blood-based screening test for colorectal cancer in adults aged 45 and older—the company's first commercial product. Partner Abbott will exclusively commercialize it in the U.S. starting this fall, competing with Guardant Health's Shield test. The test detects cancer signals from circulating DNA fragments. In a 48,000-person study, it showed 81.1% sensitivity for colorectal cancer and 13.7% for advanced precancerous growths

MORE DETAILS

Roche receives FDA clearance for the cobas® BV/CV assay, enabling fast and highly accurate vaginitis diagnosis

2026-07-27

Roche received FDA 510(k) clearance for its cobas® BV/CV assay, a molecular diagnostic test that detects Bacterial vaginosis and Candida vaginitis from a single vaginal swab. Traditional methods like microscopy have nearly 50% misdiagnosis rates. The PCR-based test improves accuracy, aligning with CDC guidelines. It integrates with Roche's sexual-health portfolio, enabling concurrent STI testing from one sample. Bacterial vaginosis affects ~27% of North American women of reproductive age.

MORE DETAILS

Seegene USA Receives FDA Emergency Use Authorization for Multiplex PCR Assay, Advancing Differential Diagnosis of HSV-1&2, VZV, and Monkeypox Virus for Ulcerative Skin Lesions

2026-07-23

MORE DETAILS

Initiatives Look to Strengthen Vaccine Policy and Governance in US

2026-06-23

Two new complementary initiatives from CIDRAP’s Vaccine Integrity Project and The Evidence Collective aim to evaluate and improve US vaccine policymaking, governance, and public trust amid ongoing changes to the nation's immunization infrastructure.

MORE DETAILS

Go to page

About us: Our products include chemicals and biologicals for scientific research in biology (cell biology, molecular biology and protein biology research), vaccine generation and production, biomedical diagnosis. and veterinary hygiene. Our company alos provides high quality products, optimal advanced technology solutions to help customers accelerate the progress of transitioning their research products to manufacturing or serving the medical care.
We distribute reagents, consumables and laboratory equipment for molecular biology, biotechnology, biochemistry, molecular diagnostics, quality control, tissue culture, forensic as well as genomics, proteomics and in vitro fertilization centers. We represent companies of recognized trajectory and, together with them, we are committed to the development and productive efficiency in science.

View More

Contact Us: 14F, Oriental-Weiye Square, No.609 Yinxiang Road, Jiading District, Shanghai, PR.CHINA; beyondbiotech@126.com; Phone:+86-021-60959250 Mob: +86-15901864269 Whatsapp:+86 15901864269

Newsletter: Lorem ipsum dolor si consectetur adipisicing elit, sed eiusmotempor incididunt ut labore et

Follow Us